ineligible for autologous stem cell transplant. The new first-line indication joins two previous approvals of the CD38 antibody for later-line indications, one for relapsed disease with ...

Since 2018, the J&J med has been the lone CD38 antibody approved for first-line myeloma. For that Darzalex approval, the FDA cleared the med to be paired with bortezomib, melphalan and prednisone ...

The FDA’s approval cleared the Sanofi cancer quadruplet in newly diagnosed patients who are not eligible for stem cell transplants. Prior to that nod, J&J’s Darzalex had been the lone CD38 ...

Daratumumab binds to CD38 and inhibits the growth of CD38 expressing tumor cells by inducing apoptosis ... myeloma who have received 1–3 prior lines of therapy; as monotherapy in patients ...

Samer A. Al'Hadidi, MD, MS, reviewed the benefits of cilta-cel in the subgroup analysis of CARTITUDE-4 in patients with ...

Operator Good morning and welcome to Johnson & Johnson's third quarter 2024 earnings conference call. All participants will ...

Johnson & Johnson’s Tecvayli (teclistamab) has been recommended by NICE as a first-line treatment for myeloma in England and ...

Johnson & Johnson linked Carvykti to a 45% reduction in risk of death and Darzalex to a 61% improvement in minimal residual ...

Poseida Therapeutics' lead allogeneic chimeric antigen receptor T-cell candidate it is co-developing with Roche will advance to Phase Ib.

TSVT announced that it will discontinue enrollment in its ongoing phase III KarMMa-9 study.The study is evaluating Abecma ...

as a first-line treatment option for adult patients with newly diagnosed multiple myeloma (NDMM) who are not eligible for autologous stem cell transplant (ASCT). Also Read: Sanofi’s Tolebrutinib ...